Skip to main content

Advertisement

SpringerLink
Log in

Preoperative Utility of the Glasgow Prognostic Score on Outcomes of Patients with Locally Advanced Gastric Cancer

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

To assess the utility of the Glasgow Prognostic Score (GPS) obtained before curative resection for predicting outcomes in patients with advanced gastric cancer (GC).

Methods

This study retrospectively analyzed the outcomes of 337 consecutive patients with GC who underwent curative surgery for locally advanced gastric cancer between January 2003 and June 2014. GPS was assessed within 4 days prior to surgery.

Results

The number of patients with GPS scores of 0, 1, and 2 was 302, 26, and 9, respectively. There was significantly more blood loss during surgery and more postoperative complications in the GPS 1/2 group than in the GPS 0 group. Patients in the GPS 1/2 group had significantly poorer overall survival than those in the GPS 0 group (p = 0.001). On multivariate analysis, GPS 1/2 was identified as an independent factor for poor survival (p = 0.019).

Conclusion

GPS before curative resection might be a useful predictive factor for perioperative complications and survival in locally advanced GC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

Clinical database consisting of 636 consecutive patients who underwent gastrectomy for advanced GC between January 2003 and June 2014 at Kanagawa Cancer Center was used for this study.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  Google Scholar 

  2. International Agency for Research on Cancer [Internet] GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. [cited 2018 Jan 4] Available from: http://globocan.iarc.fr/.

  3. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.

    Article  CAS  Google Scholar 

  4. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ, CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.

    Article  CAS  Google Scholar 

  5. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.

    Article  Google Scholar 

  6. Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, Guthrie GK, Horgan PG, McMillan DC. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One. 2012;7(8):e41883.

    Article  CAS  Google Scholar 

  7. Vashist YK, Loos J, Dedow J, Tachezy M, Uzunoglu G, Kutup A, Yekebas EF, Izbicki JR. Glasgow Prognostic Score is a predictor of perioperative and long−term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol. 2011;18(4):1130–8.

    Article  Google Scholar 

  8. Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, Tanaka C, Nakyama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow Prognostic Score is the most reliable parameter. Medicine. 2016;95(18):e3582.

    Article  CAS  Google Scholar 

  9. Li M, Bi X, Li Z, Huang Z, Han Y, Zhou J, Zhao J, Zhang Y, Zhao H. Prognostic role of Glasgow Prognostic Score in patient with hepatocellular carcinoma. Medicine. 2015;94(49):e2133.

    Article  CAS  Google Scholar 

  10. Dreanic J, Maillet M, Dhooge M, Mir O, Brezault C, Goldwasser F, Chaussade S, Coriat R. Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti−EGFR therapies. Med Oncol. 2013;30(3):656.

    Article  Google Scholar 

  11. Inamoto T, Matsuyama H, Sakano S, Ibuki N, Takahara K, Komura K, Takai T, Tsujino T, Yoshikawa Y, Minami K, Nagao K, Inoue R, Azuma H. The systemic inflammation−based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma. Oncotarget. 2017;8(68):113248–57.

    Article  Google Scholar 

  12. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K: ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S−1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.

  13. Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. 2011;14(2):97–100.

    Article  Google Scholar 

  14. Clavien PA, Barkun J, de Oliveria ML, Michelle L, Vauthey JN, Dindo D, Schulick R, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien−Dindo classification of surgical complications: five−year experience. Ann Surg. 2009;250(2):187–96.

    Article  Google Scholar 

  15. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4(3):250–5.

    Article  Google Scholar 

  16. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.

    Article  CAS  Google Scholar 

  17. Onate-Ocena LF, Aiello-Crocifoglio V, Gallardo-Rincon D, Herrera-Goepfert R, Brom-Vallardes R, Carillo JF, Cervera E, Mohar-Betancourt A. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14(2):381–9.

    Article  Google Scholar 

  18. Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS, Horgan P. The relationship between hypoalbuminemia, tumor volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer. 2004;91(2):205–7.

    Article  CAS  Google Scholar 

  19. Xiao Y, Zie X, Shao Z, Chen W, Xie H, Qin G, Zhao N. Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients. Medicine. 2017;96(50):e9247.

    Article  Google Scholar 

  20. Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg. 2012;203(1):101–6.

    Article  Google Scholar 

  21. Crumley ABC, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94(5):637–41.

    Article  CAS  Google Scholar 

  22. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg. 2009;249(5):788–93.

    Article  Google Scholar 

  23. Melling N, Grüning A, Tachezy M, Nentwich M, Reeh M, Uzuoglu FG, Vashist YK, Izbicki JR, Bogoevski D. Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment. Surgery. 2016;159(6):1548–56.

    Article  Google Scholar 

  24. Jiang X, Hiki N, Nunobe S, Kumagai K, Kubota T, Aikou S, Sano T, Yamaguchi T. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012;107(2):275–9.

    Article  CAS  Google Scholar 

  25. Pan QX, Su ZJ, Zhang JH, Wang CR, Ke SY. A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer. Onco Targets Ther. 2015;8:1375–85.

    Article  Google Scholar 

  26. Takeno S, Hashimoto T, Shibata R, Maki K, Shiwaku H, Yamana I, Yamashita R, Yamshita Y. Improvement of high-sensitivity inflammation-based Glasgow Prognostic Score by gastrectomy is a favorable prognostic factor in patients with gastric cancer. Anticancer Res. 2014;34(10):5695–702.

    PubMed  Google Scholar 

  27. Nozoe T, Iguchi T, Egashira A, Matsukuma A, Ezaki T. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011;201(2):186–91.

    Article  Google Scholar 

  28. Liu X, Chen S, Liu J, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Impact of systemic inflammation on gastric cancer outcomes. PLoS One. 2017;12(3):e0174085.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2−3−2 Nakao Asahi Yokohama, Kanagawa, 241-8515, Japan

    Yota Shimoda, Hirohito Fujikawa, Keisuke Komori, Hayato Watanabe, Kazuki Kano, Takanobu Yamada, Manabu Shiozawa, Soichiro Morinaga, Takashi Ogata & Takashi Oshima

  2. Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan

    Yota Shimoda, Kenji Katsumata & Akihiko Tsuchida

Authors
  1. Yota Shimoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hirohito Fujikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keisuke Komori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hayato Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuki Kano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takanobu Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manabu Shiozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Soichiro Morinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kenji Katsumata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akihiko Tsuchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takashi Ogata
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Takashi Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization and study design were undertaken by Yota Shimoda and Hirohito Fujikawa. Statistical analysis and interpretation were performed by Yota Shimoda and Hirohito Fujikawa. Interpretation of data was performed by all investigators. The article and figures were drafted by Yota Shimoda, Hirohito Fujikawa, and Takashi Oshima. Finally, this article was revised and approved by all investigators, and all authors actively participated in this study.

Corresponding authors

Correspondence to Hirohito Fujikawa or Takashi Oshima.

Ethics declarations

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics Approval

This study was approved prior to initiation by the Research Ethics Committee of the Kanagawa Cancer Center (approval number: Epidemiological Study-2019-138).

Consent to Participate

All study participants provided informed consent.

Consent for Publication

All study participants provided consent for publication.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shimoda, Y., Fujikawa, H., Komori, K. et al. Preoperative Utility of the Glasgow Prognostic Score on Outcomes of Patients with Locally Advanced Gastric Cancer. J Gastrointest Canc 53, 265–271 (2022). https://doi.org/10.1007/s12029-021-00584-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-021-00584-3

Keywords

Search

Navigation